肌萎缩侧索硬化患者平均生存期的变化(1995-2018):来自皮埃蒙特和瓦莱达奥斯塔登记处的结果
该研究基于PARALS登记处24年数据,分析3,134例ALS患者生存趋势。中位生存期在第一和第二时段保持稳定(18.6个月 vs 18.3个月),第三时段改善至20.1个月(p=0.0041),HR为0.76(95% CI 0.67-0.87,p=0.00003)。亚组分析显示2013-2018时段持续生存优势(HR 0.77,95% CI 0.65-0.90),且生存获益仅见于中等进展者(HR 0.60,95% CI 0.45-0.80)。
要点
- 第三时段(2011-2018)中位生存期20.1个月,较前两时段18.6和18.3个月改善。
- 第三时段较第一时段死亡风险降低,HR 0.76(95% CI 0.67-0.87)。
- 生存获益仅见于中等进展者,HR 0.60(95% CI 0.45-0.80)。
核心结论
- 在PARALS中,ALS患者生存期随时间增加。
- 亚组分析中,时段的有益效应仅见于中等进展者。
- 三级中心提供的多学科护理改善可能是该发现的一种可能解释,但需进一步专门研究证实此假设。
研究设计与样本
- 基于人群的队列研究,使用皮埃蒙特和瓦莱达奥斯塔ALS登记处(PARALS)数据。
- 共纳入3,134例患者,按诊断日期分为第一(1995-2002)、第二(2003-2010)和第三(2011-2018)时段,分别为990、1,023和1,121例。
- 生存期定义为从诊断到死亡、气管造口或删失日期的时间。
- 采用Cox比例风险模型,以诊断时段为主要变量,调整性别、起病部位、起病年龄、诊断延迟、诊断时用力肺活量、起病至诊断的Δ体重指数、无创机械通气使用、胃造瘘使用和随访地点。
- 亚组分析比较2007-2012和2013-2018队列,额外纳入利鲁唑处方、遗传学和preslope分类作为协变量。
主要发现
- 中位生存期在第一和第二时段保持稳定(18.6个月 vs 18.3个月),第三时段改善至20.1个月(p=0.0041),HR为0.76(95% CI 0.67-0.87,p=0.00003)。
- 亚组分析中,最近时段(2013-2018)显示持续生存优势(HR 0.77,95% CI 0.65-0.90)。
- 生存获益仅见于中等进展者(HR 0.60,95% CI 0.45-0.80)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The average survival of patients with amyotrophic lateral sclerosis (ALS) ranges from 2 to 5 years from symptom onset. However, it remains unclear whether this estimate has improved over time. The objective of this study was to analyze the survival trend of a large population-based cohort of patients with ALS over a 24-year period. METHODS: Patients from the Piemonte and Valle d'Aosta registry for ALS (PARALS) were categorized into the first (1995-2002), second (2003-2010), or third (2011-2018) epoch based on their diagnosis date. Survival was defined as the time from diagnosis to death, tracheostomy, or censoring date. A Cox proportional hazard model was developed with diagnosis epoch as the primary variable of interest, adjusted for sex, site of onset, age at onset, diagnostic delay, forced vital capacity at diagnosis, Δbody mass index from onset to diagnosis, noninvasive mechanical ventilation use, gastrostomy use, and site of follow-up. A subset analysis comparing the 2007-2012 and 2013-2018 cohorts was conducted, incorporating riluzole prescription, genetics, and preslope category as additional covariates. RESULTS: A total of 3,134 patients were included, evenly distributed across the 3 epochs (990, 1,023, and 1,121, respectively). The median survival remained stable during the first and second epoch (18.6 months vs 18.3 months) but improved during the third epoch (20.1 months; p = 0.0041), with a hazard ratio (HR) of 0.76 (95% CI 0.67-0.87, p = 0.00003). In the subset analysis, the most recent epoch (2013-2018) showed a continued survival advantage (HR 0.77, 95% CI 0.65-0.90). Of interest, the survival benefit was only evident among intermediate progressors (HR 0.60, 95% CI 0.45-0.80). DISCUSSION: In the PARALS, ALS survival increased over time. In a subset analysis, the beneficial effect of the epoch was only evident among intermediate progressors. The improvement in multidisciplinary care provided by tertiary centers may be one possible explanation for this finding, although further dedicated studies are needed to confirm this hypothesis.
引用
- Vasta R, De Mattei F, Tafaro S, et al. Changes to Average Survival of Patients With Amyotrophic Lateral Sclerosis (1995-2018): Results From the Piemonte and Valle d'Aosta Registry. Neurology. 2025. PMID: 40127392. doi:10.1212/WNL.0000000000213467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。